文献速递流行病学与生物统计临床试验与 GCP

2026-2027呼吸道季节流感疫苗有效性与安全性证据综述

Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.
PubMed 文献 · JAMA · 2026-09-02

该系统综述检索2025年8月至2026年6月发表的文献,纳入69项研究,评估美国获批季节性流感疫苗的有效性与安全性。结果显示疫苗与老年人住院和死亡风险降低相关,对儿童和青少年流感相关死亡有保护作用,妊娠期接种对婴儿有保护,未发现新的安全性问题。

要点

  • 流感疫苗可降低老年人流感相关住院和死亡风险
  • 儿童和青少年接种对实验室确诊流感相关死亡VE为80.0%
  • 未发现流感疫苗与严重不良事件风险增加相关

核心结论

  • 2025年8月至2026年6月发表的证据持续表明流感疫苗与重症和住院风险降低相关。
  • 未发现新的安全性问题。

研究设计与样本

  • 系统综述检索Medline、Embase、Cochrane CENTRAL和Scopus,时间范围为2025年8月1日至2026年6月30日。
  • 共纳入69项符合条件的研究:21项随机临床试验、23项有对照组的观察性研究、7项无对照组的产品安全性研究和18项疾病负担描述性研究。

主要发现

  • 老年人中流感疫苗与流感相关住院风险降低相关,VE范围为19.0%(95% CI,0.0%-34.0%)至43.0%(95% CI,30.0%-53.0%)。
  • 老年人中流感疫苗与死亡风险降低相关,VE范围为29.0%(95% CI,16.0%-40.0%)至65.8%(95% CI,54.6%-76.9%)。
  • 6月龄至17岁婴儿、儿童和青少年中,基于8个季节国家监测数据的病例队列分析报告,疫苗对实验室确诊流感相关死亡的VE为80.0%(95% CI,75.0%-84.0%)。
  • 基于2011年至2022年回顾性队列研究,妊娠期接种疫苗对婴儿有症状疾病的VE为44.4%(95% CI,31.4%-54.9%)。
  • 2025年发表的2022至2025季节RCT数据显示,老年人中高剂量疫苗相比标准剂量疫苗对住院的相对VE为43.6%(95% CI,27.5%-56.3%)。

关键数值与推荐

  • 纳入标准为报告美国流感流行病学或美国获批任何流感疫苗配方有效性与安全性的英文研究。
  • 数据提取涵盖老年人、成人、妊娠期、婴儿儿童和年轻成人以及免疫受损人群的有效性与安全性估计。
  • 进行了偏倚风险评估。

临床怎么用

  • 应继续推荐季节性流感疫苗接种,尤其针对老年人、婴幼儿、儿童和年轻成人等高危人群。
  • 妊娠期接种流感疫苗可同时保护孕妇和婴儿。
  • 老年人可考虑高剂量流感疫苗以进一步降低住院风险。
  • 流感疫苗单独接种或与呼吸道合胞病毒或COVID-19免疫接种同时接种未显示严重不良事件风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Influenza continues to cause significant mortality and morbidity in the US. Seasonal influenza vaccines reduce the severity of disease and prevent hospitalizations and death, especially among individuals at high risk. OBJECTIVE: To identify and summarize the most recently published research spanning several influenza seasons reporting on the epidemiology of influenza in the US and the effectiveness and safety of US-licensed seasonal influenza vaccines, updating a prior evidence review through August 2025. EVIDENCE REVIEW: This systematic review searched Medline (PubMed), Embase, Cochrane CENTRAL, and Scopus from August 1, 2025, through June 30, 2026, for all English-language studies. Eligible publications reported on the epidemiology of influenza in the US or vaccine effectiveness and safety for any influenza vaccine formulation approved for use in the US. Data extraction included effectiveness and safety estimates reported among older adults; adults; during pregnancy; infants, children, and young adults; and persons who were immunocompromised. Risk of bias assessment was conducted. FINDINGS: The search identified 69 eligible studies: 21 randomized clinical trials (RCTs) and 23 observational studies with a comparator group, 7 product safety studies without a comparator group, and 18 descriptive studies of disease burden. Across multiple seasons, influenza vaccines were associated with reduced risk of influenza-related hospitalization (vaccine effectiveness [VE] ranging from 19.0%; 95% CI, 0.0%-34.0% to 43.0%; 95% CI, 30.0%-53.0%) and mortality (VE ranging from 29.0%; 95% CI, 16.0%-40.0% to 65.8%; 95% CI, 54.6%-76.9%) among older adults. Vaccines were also associated with reduced risk of severe influenza among infants, children, adolescents, and young adults; a case-cohort analysis of national surveillance data over 8 seasons (2016-2020 and 2021-2025) among infants, children, and adolescents aged 6 months to 17 years reported that VE was 80.0% (95% CI, 75.0%-84.0%) against laboratory-confirmed influenza-associated deaths. Vaccination during pregnancy was associated with a VE against symptomatic disease in infants of 44.4% (95% CI, 31.4%-54.9%) based on a retrospective cohort study from 2011 to 2022. RCT data published in 2025 for seasons 2022 to 2025 reported higher efficacy against hospitalization with the high-dose compared with standard-dose vaccine among older adults (relative VE, 43.6%; 95% CI, 27.5%-56.3%). A large self-controlled case series among 9 973 703 individuals receiving vaccines found no association with increased risk of serious adverse events, including Guillain-Barré syndrome, after the seasonal influenza vaccine was administered alone or when coadministered with respiratory syncytial virus or COVID-19 immunizations. Another self-controlled case series reported no association with increased risk of febrile seizure during the interval 0 to 7 days after vaccination. CONCLUSIONS AND RELEVANCE: This systematic review found that evidence published August 1, 2025, through June 30, 2026, continued to demonstrate that influenza vaccines were associated with reduced risk of severe disease and hospitalization, especially among older adults, infants, children, and young adults. No new safety concerns were identified.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Senerth E, Sheikholeslamian SM, Sivakumaran K, et al. Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season. JAMA. 2026. PMID: 42684248. doi:10.1001/jama.2026.18126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。